STAGE IIIA OVARIAN CANCER AJCC V8
Clinical trials for STAGE IIIA OVARIAN CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA OVARIAN CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA OVARIAN CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat cancers? drug targets gene glitches in advanced tumors
Disease control OngoingThis phase 2 study tests the drug pembrolizumab in 21 people with advanced solid tumors that have specific gene changes (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or stop the cancer from growing. This is not a cure, but a way to control the disease.
Matched conditions: STAGE IIIA OVARIAN CANCER AJCC V8
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 01, 2026 15:29 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial tests the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer. Participants take olaparib for two cycles before their planned surgery to see if it can shrink tumors safely. The goal is to find out if thi…
Matched conditions: STAGE IIIA OVARIAN CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC